AzTrials
AzTrials

Bowel Cancer ScreeningNCT07376694

Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford

A study testing Bowel cancer screening kit in people with Bowel Cancer Screening, run by University of Hull at 1 site in United Kingdom.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Bowel cancer is the second most common cause of cancer related deaths in England. Bowel cancer screening can reduce bowel cancer deaths by detecting bowel cancer early. Previous research has shown that screening can lower a person's risk of dying from bowel cancer by over 25%. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Bowel Cancer Screening
What is being tested?
Bowel cancer screening kit
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,300 participants
Where
1 siteUnited Kingdom
Study dates
1 Nov 2024to 30 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients registered with one of 17 participating GP practices in Bradford
  • Patients invited for bowel cancer screening during the implementation period

Who cannot join

  • Individuals who are self-referrals
  • Type 2 objectors

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Northeast Bowel cancer Screening Hub

    Gateshead, Yorkshire

Other trials in United Kingdom

About this study

Bowel cancer is the second most common cause of cancer related deaths in England. Bowel cancer screening can reduce bowel cancer deaths by detecting bowel cancer early. Previous research has shown that screening can lower a person's risk of dying from bowel cancer by over 25%. In England, the NHS offers free bowel cancer screening for adults aged 60 - 74 years who are registered with a GP every two years, but screening uptake remains poor among those in deprived areas and amongst minority ethnic groups. In socioeconomically deprived areas like Bradford, where there is a high proportion of South Asian residents, bowel cancer screening uptake is low compared to other parts of England. The investigators previous research has shown that people of South Asian ethnicity are limited by many factors beyond language barriers and thus require culturally tailored approaches to facilitate uptake.

For this study, the investigators will aim to answer the question: 'Does a culturally tailored enhanced screening kit, comprising an instruction letter and booklet, and a bio-degradable poo catcher increase bowel cancer screening uptake among South Asians living in Bradford?'. Over a 6-month period, individuals registered in 17 GP practices in Bradford and due to receive their NHS bowel cancer screening invitation will be assigned to two groups: standard kit (usual screening kit only) and enhanced kit (culturally tailored instruction letter and biodegradable poo catcher). Uptake of bowel cancer screening among South Asian participants in each group will be assessed 13 weeks after the identification of the final participant. The findings of this study will provide valuable information for policy makers about how to address population specific barriers to bowel cancer screening using culturally tailored approaches in the UK.

Read the detailed description

Bowel cancer is the fourth most common cancer and the second leading cause of cancer deaths in England. Screening can improve survival by detecting cancer earlier, when cancer is easier to treat. However, participation in screening is sub-optimal, and there are ethnic and regional inequalities in uptake. Indeed, in 2022, uptake of bowel cancer screening in Yorkshire and Humber was 72.2% overall, but only 67.8% in Bradford, where there is a high proportion of South Asian residents (uptake of bowel cancer screening in England has been shown to be 50% lower among South adults, compared with White British adults).

Universal approaches attempting to increase the uptake of bowel cancer screening, such as text-message reminders, have been shown to be effective, but tend to be inaccessible to those whose first language is not English and, thus, may widen health inequalities. In addition, recent research indicates that a plethora of culturally specific barriers, over and above language barriers, prohibit participation in bowel cancer screening by South Asian individuals. Thus, culturally tailored approaches, which address population-specific barriers, are needed to ensure equitable access to, and uptake of, screening.

The investigators have spent the past two years working with South Asian communities to understand their barriers to participation, and have identified the following barriers to completing the test: 1) lack of knowledge about bowel cancer and screening (knowledge); 2) lack of language, literacy and physical ability (skills) to carry out the home test; 3) confidence to carry it out correctly (belief about capabilities); 4) appropriate space and time to carry out the test (environmental context and resources); 5) putting off undertaking the test (memory attention and decision processes); 6) risk perception and fear of cancer (emotions).

Mapping previous findings onto the Theoretical Domains Framework (in red) and, subsequently, the Behaviour Change Technique Taxonomy (BCTT), research suggests that interventions which include 'education/information', 'persuasion', 'modelling' and 'enablement' functions (as defined by the BCTT) could address the barriers and increase the completion rate of the home-based bowel cancer screening test (among South Asian adults).

To address the identified barriers, and implement the above functions (in blue) the investigators propose a multifaceted intervention, comprising: 1) an easy to use and hygienic biodegradable poo catcher compared with the standard faecal immunochemical test kit (enablement) [see Appendix A]; 2) an instruction letter and booklet, with additional information on bowel cancer and screening, provided in English and multiple South Asian languages (enablement and education/information); 3) links to YouTube videos on how to use the biodegradable poo catcher (modelling and persuasion) [see Appendix A].

Being tested
Bowel cancer screening kit
Keywords
Screening, FOBT, non-randomised trial, South Asian, FIT

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bowel cancer screening kitOther

    Also called FOBT

    Home Fecal Occult Blood Test kit

Study groups in NCT07376694
Study groupRoleWhat they receive
Enhanced screening kitExperimentalCulturally tailored enhanced screening kit, comprising an instruction letter and booklet, and a bio-degradable poo catcher
Receives: Other: Bowel cancer screening kit
Usual kitActive comparatorScreening kit only
Receives: Other: Bowel cancer screening kit

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Return of bowel screening kit for testing

    % of individuals who return their bowel screening kit for foecal immunochemical testing measured using data recorded in their clinical records

    Measured: 13 weeks (screening episode)

Secondary outcomes (1)
  1. Bowel cancer screening test result

    % of individuals who screen positive for the bowel cancer screening test measured using Foecal Immunochemical Test (FIT) result recorded n clinical records

    Measured: 13 weeks (screening episode)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2026
  2. Study start1 Nov 2024
  3. Primary completion1 Apr 2026
  4. Study completion30 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07376694
Sponsor's protocol ID
RS213-332905
Status last verified
Nov 2025
First submitted
12 Jan 2026
Last updated
26 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Consent for sharing data has not been sought

Questions about this trial

What is this clinical trial studying?

A study testing Bowel cancer screening kit in people with Bowel Cancer Screening, run by University of Hull at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Return of bowel screening kit for testing (time frame: 13 weeks (screening episode)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in